Collegium Pharmaceutical (COLL) Gross Margin (2016 - 2026)
Collegium Pharmaceutical's (COLL) quarterly Gross Margin came in at 60.59% in Q1 2026, up 583.0% year-on-year from 8.87% in Q1 2025, and down 3.04% quarter-over-quarter from 62.49% in Q4 2025.
Collegium Pharmaceutical (COLL) Gross Margin (2016 - 2026) Analysis & Trends
Collegium Pharmaceutical's Gross Margin history runs 11 years deep, the most recent figure standing at 60.59% for Q1 2026.
- On a quarterly basis, Gross Margin rose 583.0% year-over-year to 60.59% in Q1 2026; TTM through Mar 2026 was 60.68%, a 1308.0% decrease from a year earlier, with the FY2025 full-year figure at 59.35%, down 41.0% from the prior year.
- Gross Margin slipped to 60.59% in Q1 2026 per COLL's latest filing, from 62.49% in the prior quarter.
- Across five years, Gross Margin topped out at 263.94% in Q4 2024 and bottomed at 35.4% in Q4 2022.
- The 5-year median for Gross Margin is 58.75% (2023), against an average of 68.2%.
- Across the five-year window, Gross Margin surged 20074 bps in 2024 and plunged 20145 bps in 2025, its largest moves.
- Year by year, Gross Margin stood at 35.4% in 2022, then surged by 79 bps to 63.19% in 2023, then jumped by 318 bps to 263.94% in 2024, then tumbled by 76 bps to 62.49% in 2025, then retreated by 3 bps to 60.59% in 2026.
- Per Business Quant, the three latest COLL Gross Margin figures stand at 60.59% (Q1 2026), 62.49% (Q4 2025), and 61.7% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 49.52% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 71.66% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 62.93% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 82.93% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 32.97% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 98.31% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 57.26% |
| 10 | Collegium Pharmaceutical | 1.14 Bn | 853.50 Mn | 117.25 Mn | 60.59% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 60.59% |
| Dec 31, 2025 | 62.49% |
| Sep 30, 2025 | 61.70% |
| Jun 30, 2025 | 57.65% |
| Mar 31, 2025 | 54.75% |
| Dec 31, 2024 | 263.94% |
| Sep 30, 2024 | 60.76% |
| Jun 30, 2024 | 62.51% |
| Mar 31, 2024 | 63.11% |
| Dec 31, 2023 | 63.19% |
| Sep 30, 2023 | 58.75% |
| Jun 30, 2023 | 54.47% |
| Mar 31, 2023 | 53.47% |
| Dec 31, 2022 | 35.40% |
| Sep 30, 2022 | 46.33% |
| Jun 30, 2022 | 42.38% |
| Mar 31, 2022 | 57.90% |
| Dec 31, 2021 | -3.48% |
| Sep 30, 2021 | 58.49% |
| Jun 30, 2021 | 60.57% |